Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Objective: The impact of intrauterine growth restriction (IUGR) on perinatal morbidity and long-term neurodevelopmental outcome has been published in numerous studies. Throughout this analysis, the influence of IUGR on the postnatal amplitude-integrated EEG (aEEG) in preterm infants below 30 weeks of gestation was assessed. The second concern was the correlation between the pattern of the aEEG in the first two weeks with neurodevelopmental outcome, comparing infants with and without IUGR.
Methods: Routinely assessed aEEG data of preterm infants with IUGR born below 30 weeks of gestation in the years 2005 until 2007 were analysed retrospectively according to the aEEG score (combining occurrence of sleep-wake-cycles, background activity and suspected seizure activity). Neurodevelopmental outcome was evaluated at 24 months using the Bayley Scales of Infant Development and standardized neurologic examination.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intrauterine growth restriction | birth weight <10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up |
| |
| Appropriate for gestation age | control group with birth weight >10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| aEEG | Other | The amplitude integrated EEG was performed using a single-channel, biparietal aEEG (CFM 6000; Natus Medical Incorporated, San Carlos, CA) |
|
| Measure | Description | Time Frame |
|---|---|---|
| aEEG score (including background pattern, occurrence of sleep-wake-cycling and presence of seizure activity) | composite score background activity (BA), occurrence of sleep-wake-cycling (SWC) and presence of seizure activity (SA) meaning score 1= normal (normal BA, SWC yes, SA no) and score 2 and 3 = abnormal (2=abnormality in 1 category (BA, SWC or SA) and score 3= abnormality in 2 or 3 categories | first 14 days of life |
| Measure | Description | Time Frame |
|---|---|---|
| Neurodevelopmental outcome | composite score: Bayley Scales of Infant Development (>85= normal, <70 severely impaired, 71-84= mildly impaired) and standardized neurologic examination (normal or abnormal) | 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Morbidity, mortality and neurodevelopmental outcome of patients with IUGR compared to controls | morbidities until discharge (Intraventricular hemorrhage, retinopathy, chronic lung disease, necrotizing enterocolitis, periventricular leucomalacia); mortality and neurodevelopmental outcome (via Bayley Scales of Infant Development >85= normal, <70 = severly impaired) | 24 months |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Retrospectively, children with intrauterine growth restriction (defined as a birth weight below the 10th percentile) treated at the Neonatal Intensive Care Unit (NICU) of the Medical University Vienna between 2005 and 2007 were included in the study. Besides IUGR, inclusion criteria were gestational age between 23+1 and 29+6 weeks and routinely assessed aEEG measurements. Infants with congenital anomalies and severe asphyxia were excluded. The control group consists of infants of the same age with normal birth weight (>10th percentile) in the same study period.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Katrin Klebermass-Schrehof, MD | Medical University of Vienna | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical University Vienna | Vienna | State of Vienna | 1090 | Austria |
Not provided
Not provided
Not provided
Not provided
|
| ID | Term |
|---|---|
| D005317 | Fetal Growth Retardation |
| D065886 | Neurodevelopmental Disorders |
| ID | Term |
|---|---|
| D005315 | Fetal Diseases |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D006130 | Growth Disorders |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001523 | Mental Disorders |
Not provided
Not provided